ArticleAlimentary pharmacology & therapeutics2015
Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies.
Article in Alimentary pharmacology & therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and meta-analysis of HIV, HBV and HCV infection prevalence in Sudan.Virology journal · 2018Pooled it
- Budget impact analysis of glecaprevir/pibrentasvir treatment for hepatitis C in Iran: a modelling study.BMJ open · 2025Article
- The Impact of New Direct-Acting Antiviral Therapy on the Prevalence and Undiagnosed Proportion of Chronic Hepatitis C Infection in Alberta: A Model-Based Analysis.Canadian liver journal · 2025Article
- Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007-2021: a nationwide, multicentre, retrospective cohort study.EClinicalMedicine · 2024Article
- Article
- Quality Assurance for Hepatitis C Virus Point-of-Care Diagnostics in Sub-Saharan Africa.Diagnostics (Basel, Switzerland) · 2023Review
- Treatment as prevention for hepatitis C virus in the Middle East and North Africa: a modeling study.Frontiers in public health · 2023Article
- Challenge of managing hepatitis B virus and hepatitis C virus infections in resource-limited settings.World journal of hepatology · 2022Review
- Pursuing Elimination of Hepatitis C in Egypt: Cost-Effectiveness and Economic Evaluation of a Country-Wide Program.Infectious diseases and therapy · 2022Article
- Egypt's Ambitious Strategy to Eliminate Hepatitis C Virus: A Case Study.Global health, science and practice · 2021Article
- Circulatory miRNA-484, 524, 615 and 628 expression profiling in HCV mediated HCC among Egyptian patients; implications for diagnosis and staging of hepatic cirrhosis and fibrosis.Journal of advanced research · 2020Article
- Hepatitis C elimination: a Public Health Perspective.Current treatment options in gastroenterology · 2019Review
- MicroRNA-215 as a Diagnostic Marker in Egyptian Patients with Hepatocellular Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- Treatment as prevention for hepatitis C virus in Pakistan: mathematical modelling projections.BMJ open · 2019Article
- Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.World journal of gastroenterology · 2019Article
- Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations.World journal of gastroenterology · 2018Review
- The Estimation of Economic Burden of Hepatitis C Virus Infection in Iran.Iranian journal of public health · 2018Article
- The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up.Health policy and planning · 2018Article
- Qualitative case study of needle exchange programs in the Central Appalachian region of the United States.PloS one · 2018Article
- Prevalence of HCV Infection in Household Contacts of Chronic Liver Diseases Cases in Egypt.Journal of environmental and public health · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prevalence of hepatitis C virus (HCV) infection in Egypt is the highest in the world, yet the total economic burden has not been quantified. Improved understanding of costs and the impact of treatment strategies will provide for better allocation of resources to reduce HCV disease and economic burden.
aimA modelling approach was used to quantify the current HCV-infected population, future disease progression and associated costs in Egypt.
methodsDirect healthcare costs were calculated from a nationally representative hospital and a disability adjusted life year (DALY) template was used with monetary value assigned to lost life years. Three scenarios were considered: (i) Historical treatment scenario: 50% SVR; 65,000 treated annually, (ii) Current treatment scenario: 90% sustained virologic response (SVR); 65,000 treated annually, (iii) Increased treatment scenario: 90% SVR; 325,000 treated annually by 2018.
resultsCumulative DALYs (2015-2030) under Scenario 1 were estimated at 7.88 million and cumulative costs estimated at $89.07 billion. Annual DALYs increased 16% during 2015-2030 while annual costs more than doubled. Scenario 2 reduced cumulative DALYs and costs by 7% and 4%, respectively. Under Scenario 3, total costs declined 73% to $1047 million during 2015-2030. As compared to Scenario 1, cumulative DALYs and costs decreased 37% and 35%, respectively.
conclusionsThis is the first estimate of the total economic burden of HCV in Egypt. Extraordinary measures are necessary to substantially reduce HCV disease and cost burden. With newer therapies, strategies to reduce disease burden are feasible and cost-effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.